Immunovant’s chief technology officer sells $25,835 in stock

Immunovant, Inc. NASDAQ:IMVT Chief Technology Officer Jay S. Stout, sold 1,585 shares of common stock on October 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transactions amounted to $25,835. The stock, currently trading at $17.03 with a market capitalization of $2.98 billion, has seen its share price decline 29% year-to-date. InvestingPro analysis shows the company maintains a strong balance sheet with cash exceeding debt.

The shares were sold at a weighted average price ranging from $16.06 to $16.48 per share.

Following the transaction, Stout directly owns 203,334 shares of Immunovant. The sale was to cover tax obligations related to the vesting of restricted stock units.

In other recent news, Immunovant announced that approximately 80% of patients with uncontrolled Graves’ disease maintained normal thyroid function six months after completing treatment with its experimental therapy, batoclimab. The promising results showed that 17 out of 21 patients who completed the follow-up period demonstrated a sustained response, with nearly half achieving remission without needing additional anti-thyroid drugs. Oppenheimer reiterated its Outperform rating for Immunovant, highlighting the "inspiring remission data" and setting a price target of $54.00. Meanwhile, Stifel adjusted its price target to $50.00 from $61.00, maintaining a Buy rating, and noted the potential of the FcRn class as a significant opportunity in the market.

In leadership news, Immunovant appointed Eric Venker as CEO, formalizing his role with a new compensation agreement. Under this agreement, Dr. Venker will receive an annual base salary of $672,000 and be eligible for a performance bonus. Additionally, Goldman Sachs resumed coverage of Immunovant with a Neutral rating and set an $18.00 price target, acknowledging the potential of IMVT-1402 in treating Graves’ disease and possibly cutaneous lupus erythematosus. These developments reflect the company’s ongoing strategic and research efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.